Introduction
============

Inherited diseases are frequently found worldwide and a major group of inherited diseases is autosomal recessive disorders such as non-syndromic hereditary hearing impairment, Fukuyama congenital muscular dystrophy, Wilson disease and xeroderma pigmentosum. The carrier frequencies of these diseases are estimated to be 0.9% for Fukuyama congenital muscular dystrophy,^[@bib1]^ 1.1% for Wilson disease^[@bib2]^ and 0.9% for xeroderma pigmentosum (see the Japan Intractable Disease Information Center\'s website: <http://www.nanbyou.or.jp/entry/112>). The mutation spectrum of these diseases is reported to be population specific.^[@bib1],\ [@bib3]^ Among these autosomal recessive disorders, non-syndromic congenital hearing impairment is reported to be the most frequent.^[@bib4],\ [@bib5],\ [@bib6]^ Approximately 1 in 1000 new-born children are affected by congenital hearing impairment, and 50--60% cases of them are attributable to genetic causes.^[@bib7]^ Hereditary hearing loss has considerable genetic heterogeneity and, to date, more than 100 genetic loci have been discovered to be the cause.^[@bib8]^ Genetic testing for congenital hearing impairment has become more important for accurate diagnoses, prediction of severity of hearing loss, estimation of associated abnormalities, selection of appropriate habilitation options, prevention of hearing loss and better genetic counseling.^[@bib9]^ Recently, the panel screening of multiple mutations by invader assay^[@bib10]^ was reported to be very efficient.^[@bib9]^ Genetic testing by invader assay is now performed throughout Japan, and the Japanese National Health Insurance began to cover its costs from April 2012. Currently, hearing-impaired patients can easily access clinical diagnostic screening by genetic testing, which should be accompanied by the appropriate genetic counseling that includes an estimation of the next generation\'s incidence (or recurrence) of hearing difficulty.

Most hereditary impairment is caused by recessive mutations in genes such as *GJB2* and *SLC26A4*.^[@bib7]^ In the case of autosomal recessive disorders, patients have mutations in both the paternal and maternal alleles. Therefore, to estimate the next generation\'s incidence ratio, the carrier frequencies of the mutations in these genes must be ascertained. However, there are only a limited number of reports about the carrier frequencies of autosomal recessive disorders, such as hearing impairment, in the Japanese population.^[@bib5],\ [@bib6]^

The *GJB2* gene is the most prevalent for congenital hearing loss^[@bib11],\ [@bib12]^ and the mutation spectrums are known to vary among different ethnic groups.^[@bib6]^ It is vital to study the carrier frequency and mutation spectrum of each genetic background to enable more precise genetic counseling. The *GJB2* gene encodes connexin26, a member of the connexin family of proteins that are constituents of the intercellular gap junction.^[@bib13]^ The first *GJB2* mutation was reported by Kelsell *et al.* in 1997^[@bib14]^ and since then more than 100 pathogenic variants have been reported worldwide (see the Connexin-deafness website: <http://davinci.crg.es/deafness/>). In a previous report, *GJB2* mutations were estimated to be responsible for about 15--20% of the cases of deafness^[@bib7]^ in the US, and 12.5% (33/264) of those in Japan.^[@bib9]^ The c.35delG mutation is the most common in the Caucasian population, and the c.235delC and p.Val37Ile mutations are the most prevalent in the Asian population.^[@bib6],\ [@bib15]^ The carrier frequency of *GJB2* mutations in the control population is reported to be 2--4%^[@bib15],\ [@bib16],\ [@bib17]^ in the US, in Europe, and in Korea, but the carrier frequency in the Japanese population has not yet been reported. The information about both the carrier frequency and spectrum with respect of *GJB2* mutations in Japan is very important because *GJB2* mutations were reported to have a phenotype--genotype correlation.^[@bib18],\ [@bib19]^

The purpose of this study is to investigate the carrier frequency of *GJB2* mutations and the mutation spectrum in the Japanese population to provide more accurate information for genetic counseling. This is the first study in Japan to estimate the carrier frequency of the *GJB2* mutations causing hereditary hearing loss, the most frequent autosomal recessive disorder in Japan.

Subjects and methods
====================

Experiments were approved by the Kyoto University Graduate School and Faculty of Medicine, Ethics Committee (Permit number: G294), and written informed consent was obtained from each participant prior to genetic analysis. Blood samples were collected from 509 healthy Japanese people (201 males and 308 females) at annual health checks in Yakumo, Hokkaido in Japan. Their ages ranged from 40 to 91 years, and the average was 67.8 years. According to the questionnaire filled in by the subjects, 56/509 (11.0%) had subjectively experienced hearing difficulty, and in terms of vestibular function, 106/509 (20.8%) had experienced vertigo or dizziness. From the blood sample, we measured HbA1c (NGSP; National Glycohemoglobin Standardization Program) levels and 36 out of 509 people (7.1%) were over 6.5, revealing a risk of diabetes, which is compatible with Japanese general population. The result from our questionnaire are consistent with Japan Trak report in which 10.8% of the randomly selected 15 036 respondents reported experiencing hearing difficulty (see the Japan Trak website: <http://www.atpress.ne.jp/view/32264>). Therefore, the subjects enrolled in this study are thought to be representative of the population in Japan.

To identify *GJB2* mutations, a fragment containing the entire coding region were amplified from genomic DNA sample by PCR using the primer pair 5′-GGTGAGGTTFTFTAAGAGTTGG-3′/5′-CTACGGTGTTACTCGAGACGA-3′, and the amplicon were used as a template for direct sequencing.^[@bib5]^ Direct sequencing analysis was performed using an ABI PRISM Genetic Analyzer (Applied Biosystems, Waltham, MA, USA), and the data were analyzed using ABI Variant Reporter v1.1 (Applied Biosystems).

Results
=======

[Table 1](#tbl1){ref-type="table"} summarizes the variants identified in this study. Among the mutations screened by the invader assay,^[@bib9]^ which are covered by Japanese health insurance, we found six previously reported pathogenic variants within the coding region of *GJB2.* In detail, we detected nine alleles for p.Val37Ile, eight for c.235delC, one for p.\[Gly45Glu;Tyr136\*\], one for p.Arg143Trp, one for p.Ile71Thr and one for p.Phe191Leu; p.Gly45Glu and p.Tyr136\* mutations are on the same parental allele.^[@bib19]^ Among these mutations, the pathogenicity of p.Ile71Thr and p.Phe191Leu has been controversial, and they are considered to represent non-pathogenic polymorphisms.^[@bib6]^ We also found previously reported variants, p.Thr8Met and p.Arg127His, and two novel variants, p.Cys60Tyr and p.Phe106Leu, which were not included in the Invader assay-based mutation screening. The pathogenicity of p.Thr8Met, and p.Arg127His variants is unknown.

We found 19 previously reported pathogenic variants, and 5 variants found in this study were unclassified, so the carrier frequency of the *GJB2* mutations is estimated to be at least 3.73--4.72% (19--24/509). We believe that the screening (including the four variants, p.Thr8Met, p.Ile71Thr, p.Arg127His and p.Phe191Leu, and other novel variants) will be very important for more accurate genetic testing. The pathogenicity of novel variants is not clear and requires further studies for clarification.

The two novel variants mentioned above, p.Cys60Tyr and p.Phe106Leu, and one silent variant, p.Val63Val (c.189G\>T), were identified in this study. [Figure 1](#fig1){ref-type="fig"} shows amino acid sequences of *Homo sapiens* and other species\' connexin26 and the two novel variants, p.Cys60Tyr and p.Phe106Leu. Cys60 is evolutionarily conserved, while the leucine residue of p.Phe106Leu is found in *Xenopus laevis*. To predict the effect of the variants, we carried out computer analysis using the Sorting Intolerant from Tolerant (SIFT: <http://sift.jcvi.org/>) and Polymorphism Phenotyping (PolyPhen2: <http://genetics.bwh.harvard.edu/pph2/>). The functional prediction of p.Cys60Tyr was Damaging (1.0) by SIFT, and Damaging (1.0) by PolyPhen2. On the other hand, that of p.Phe106Leu was Tolerated (0.23) by SIFT and Benign (0) by PolyPhen2. Considering these data, p.Cys60Tyr is expected to be pathogenic and p.Phe106Leu to be a non-pathogenic polymorphism.

Synonymous variants are usually non-pathogenic unless the nucleotide change alters the splicing of the RNA. Analysis of the p.Val63Val (c.189G\>T) synonymous variant using the prediction program NNSPLICE (<http://www.fruitfly.org/seq_tools/splice.html>) indicates that this variant is not expected to be either a donor or an acceptor site for splicing and is, therefore, likely to be non-pathogenic. The three subjects carrying p.Cys60Tyr, p.Phe106Leu or p.Val63Val had no experience of hearing difficulty or tinnitus.

We found six alleles of the p.Thr123Asn mutation, but we did not consider them to be pathogenic variants; p.Thr123Asn has been considered to be a rare non-pathogenic variant because it was found with equal frequency in patients and controls in Ohtsuka.^[@bib6]^ In contrast, the non-pathogenic variants, p.Val27Ile, p.Glu114Gly and p.Ile203Thr,^[@bib11],\ [@bib15],\ [@bib20],\ [@bib21]^ that are frequently found in the Japanese population^[@bib6]^ were also frequently observed in this study. The most common *GJB2* mutation in Caucasian people, the c.35delG mutation, was not found in these subjects, indicating differing variants among ethnic groups. All things considered, the *GJB2* carrier frequency in the Japanese population was estimated to be at least 19/509 (3.73%). We did not find any subjects who carry homozygous or compound heterozygous pathogenic mutations in this study.

Discussion
==========

There are several reports on carrier frequency and the mutation spectrum of *GJB2* mutations. In Europe, the carrier frequency of c.35delG was reported to be around 2--3%.^[@bib16],\ [@bib22],\ [@bib23]^ Green *et al.*,^[@bib15]^ reported that 14 out of 560 general people carried the c.35delG variant, so they estimated that the carrier rate of c.35delG was about 2.5% in the Midwestern USA.

In the Ashkenazi Jewish population, it was reported that the carrier frequency of c.167delT variant was 4.03% (22/546).^[@bib24]^ In the Thai population, p.Val37Ile was the most frequent variant and the carrier frequency of this variant was 17.1% (35/205)^[@bib25]^ in healthy controls. In the Korean population, the carrier frequency of p.Val37Ile was 1.35% (28/2072), and that of c.235delC was 1.25% (26/2072), and no c.35delG mutants were detected in their study.^[@bib17]^

The majorities of studies have focused only on hearing-impaired patients and their allele frequency and have not focused on the carrier frequency. Ohtsuka *et al.*^6^ reported that the frequency of the mutant alleles among hearing-impaired patients was 3.9% (96/2454) for the c.235delC mutation, and 2.5% (61/2454) for the p.Val37Ile mutation. Tsukada *et al.*^19^ reported that the mutation spectrum and frequency in a large number of Japanese hearing-impaired patients, and the c.235delC mutation allele frequency was 5.3% (142/2686), and that of p.Val37Ile was 1.8% (47/2686).

In this study, we found eight alleles of the c.235delC mutant (8/1018, 0.79%) and nine alleles of the p.Val37Ile mutant (9/1018, 0.88%) in the control population. Based on our observation, the carrier frequency of c.235delC was 1.57% (8/509), and that of p.Val37Ile was 1.77% (9/509). In addition to these two most common mutations, we found two other pathogenic variants (p.\[Gly45Glu;Tyr136\*\], and p.Arg143Trp) in this study, and the carrier frequency was estimated to be around 3.73% (19/509). Furthermore, we identified two novel variants (p.Cys60Tyr and p.Phe106Leu) whose pathogenic nature is unknown. Amino-acid conservation information and prediction by computer analysis (SIFT and PolyPhen2) indicated that p.Cys60Tyr may be pathogenic and that p.Phe106Leu would be a non-pathogenic polymorphism. In addition to these prediction method, functional studies would shed light on the pathogenesis on these variants.

In this study, we also detected two p.Thr8Met variants, one p.Ile71Thr variant, one p.Arg127His variant and one p.Phe191Leu variant, all with uncertain pathogenicity; p.Ile71Thr and p.Phe191Leu were first reported in Japanese patients.^[@bib6]^ Ohtsuka *et al.*^[@bib6]^ found four p.Ile71Thr and four p.Phe191Leu variants in 2454 alleles, but p.Ile71Thr and p.Phe191Leu were only found to be heterozygous with no other mutations being detectable; therefore, it remains a possibility that they were non-pathogenic rare polymorphisms. To date, the pathogenicity of p.Ile71Thr and p.Phe191Leu mutations has not been proven,^[@bib6],\ [@bib19]^ so they may be non-pathogenic variants. The functional prediction of p.Ile71Thr was Damaging (1.0) by SIFT and Damaging (0.972) by PolyPhen2. That of p.Phe191Leu was Damaging (0.99) by SIFT and Damaging (1.0) by PolyPhen2. The p.Thr8Met variant was first reported by Kenna *et al.*^[@bib26]^ from hearing loss patients in the US population, and it was also reported to be found in hearing-impaired patients in Japan.^[@bib9],\ [@bib19]^ The functional prediction of p.Thr8Met was Damaging (0.97) by SIFT and Possibly Damaging (0.775) by PolyPhen2. The pathogenesis of the p.Arg127His variant is controversial^[@bib17]^ as this variant was detected in one family with congenital deafness^[@bib22]^ but the variant was found in a homozygous state in individuals with normal hearing in another study.^[@bib27]^ In addition this variant was predicted to be Tolerated (0.85) by SIFT and Benign (0.001) by PolyPhen2. Considering these prediction analyses, p.Thr8Met, p.Ile71Thr and p.Phe191Leu could be pathogenic.

The carrier frequency and mutation spectrum of the Japanese population was different from those of Caucasian populations; the carrier frequency of c.35delG and c.235delC mutation is reported to be 2--3% and 0% in Caucasian,^[@bib15],\ [@bib16],\ [@bib22],\ [@bib23]^ whereas 0% and 1.57% in the present study, respectively. In addition, p.Val37Ile is revealed to be common in Asian countries; the carrier frequency was 1.77% in Japanese, 1.35% in Korea and 17.1% in Thai population, respectively.^[@bib17],\ [@bib25]^ In patients with impaired hearing, *GJB2* mutations were reported to have a phenotype--genotype correlation.^[@bib18],\ [@bib19]^ For example, the c.235delC homozygous mutation and the c.235delC/p.Arg143Trp compound heterozygous mutation show severe hearing impairment, while the p.Val37Ile homozygous mutation has a mild phenotype.^[@bib19]^

Among hearing-impaired patients in Japan, the c.235delC mutation is reported to be the most prevalent mutation.^[@bib5],\ [@bib6],\ [@bib20]^ However, in people with normal hearing, the p.Val37Ile mutation was more frequent than c.235delC in our study, as with previous studies.^[@bib19]^ This apparent contradiction may be because patients with the p.Val37Ile mutation have a milder phenotype and may therefore be excluded from the research on hearing loss.^[@bib19]^

Generally, in the case of autosomal recessive diseases, if the parents are related, the probability of a homozygous mutant allele increases. However, even if the parents are not related, it is still possible for both to be *GJB2* mutation carriers because the *GJB2* carrier frequency is estimated to be as high as around 3.7%.

In conclusion, we estimate that the *GJB2* carrier frequency of the Japanese population would be about 3.7%. Almost half of these would have the p.Val37Ile mutation, whereas individuals homozygous for this mutation have a relative mild phenotype. The other major mutation allele would be c.235delC. Our study is the latest and the largest report on carrier frequencies of *GJB2* mutations in the Japanese general population to date. This is indispensable information for predicting the next generation\'s incidence of hearing difficulty. We believe that information from this study will be useful in genetic counseling in Japan.
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![Alignment of amino-acid sequences of human and other species\' connexin26 (Cx26) showing the mutation sites of two novel variants, p.Cys60Tyr and p.Phe106Leu, and functional prediction of p.Cys60Tyr and p.Phe106Leu. We found two novel variants p.Cys60Tyr and p.Phe106Leu. To predict their pathogenesis, we compared amino-acid sequences of human and other species\' Cx26. As Cys60 is evolutionarily conserved, p.Cys60Tyr could be pathogenic; p.Phe106Leu is probably a non-pathogenic polymorphism because Xenopus has a leucine at this position. The functional prediction of p.Cys60Tyr was Damaging (1.0) by SIFT, and Damaging (1.0) by PolyPhen2. That of p.Phe106Leu was Tolerated (0.23) by SIFT and Benign (0) by PolyPhen2. Prediction by SIFT and PolyPhen2 also showed that p.Cys60Tyr would be pathogenic and p.Phe106Leu would be a non-pathogenic polymorphism.](jhg201582f1){#fig1}

###### *GJB2* variants detected in 509 Japanese people

  *Codon*                                                          *Nucleotide*             *Heterozygote*   *Homozygote*   *Frequency of mutant alleles (*n*=1018)*   *Number of persons with mutations (*n*=509)*   *Characterization of variant*       *Reference*
  ---------------------------------------------------------------- ------------------------ ---------------- -------------- ------------------------------------------ ---------------------------------------------- ----------------------------------- ---------------------------------------------------------------------------
  p.T8M                                                            c.23C\>T                 2                0              0.20%                                      2 (0.39%)                                      Unproven pathogenic nature          Kenna *et al.*^[@bib26]^
  p.G12fs[a](#t1-fn2){ref-type="fn"}                               c.35delG                 0                0              0                                          0                                              Pathogenic                          Denoyelle *et al.*,^[@bib28]^ Estivill *et al.*^[@bib22]^
  p.V27I                                                           c.79G\>A                 235              71             37.00%                                     306 (60.12%)                                   Not pathogenic                      Zelante *et al.*,^[@bib11]^ Abe *et al.*^[@bib5]^
  p.V37I[a](#t1-fn2){ref-type="fn"}                                c.109G\>A                9                0              0.88%                                      9 (1.77%)                                      Pathogenic, mild                    Wilcox *et al.*,^[@bib29]^ Abe *et al.*^[@bib5]^
  p.\[G45E; Y136X\][a](#t1-fn2){ref-type="fn"}                     c.\[134G\>A; 408C\>A\]   1                0              0.10%                                      1 (0.20%)                                      Pathogenic                          Fuse *et al.*^[@bib20]^
  p.L56fs                                                          c.167delT                0                0              0                                          0                                              Pathogenic                          Zelante *et al.*^[@bib11]^
  p.C60Y                                                           c.179G\>A                1                0              0.10%                                      1 (0.20%)                                      Unproven pathogenic nature          This study
  p.V63V                                                           c.189G\>T                1                0              0.10%                                      1 (0.20%)                                      Not pathogenic (silent variation)   This study
  p.I71T[a](#t1-fn2){ref-type="fn"},[b](#t1-fn3){ref-type="fn"}    c.212T\>C                1                0              0.10%                                      1 (0.20%)                                      Unproven pathogenic nature          Ohtsuka *et al.*^[@bib6]^
  p.L79fs[a](#t1-fn2){ref-type="fn"}                               c.235delC                8                0              0.79%                                      8 (1.57%)                                      Pathogenic                          Fuse *et al.*,^[@bib20]^ Abe *et al.*^[@bib5]^
  p.F106L                                                          c.318C\>A                1                0              0.10%                                      1 (0.20%)                                      Unproven pathogenic nature          This study
  p.R127H                                                          c.380G\>A                1                0              0.10%                                      1 (0.20%)                                      Unproven pathogenic nature          Estivill *et al.*,^[@bib22]^ Roux *et al.*^[@bib27]^
  p.E114G                                                          c.341A\>G                118              8              13.20%                                     126 (24.75%)                                   Not pathogenic                      Green *et al.*,^[@bib15]^ Fuse *et al.*^[@bib20]^
  p.T123N[a](#t1-fn2){ref-type="fn"}                               c.368C\>A                6                0              0.59%                                      6 (1.18%)                                      Not pathogenic                      Park *et al.*,^[@bib30]^ Abe *et al.*,^[@bib5]^ Ohtsuka *et al.*^[@bib6]^
  p.R143W[a](#t1-fn2){ref-type="fn"}                               c.427C\>T                1                0              0.10%                                      1 (0.20%)                                      Pathogenic                          Brobby *et al.*,^[@bib31]^
  p.F191L[a](#t1-fn2){ref-type="fn"},[b](#t1-fn3){ref-type="fn"}   c.570T\>C                1                0              0.10%                                      1 (0.20%)                                      Unproven pathogenic nature          Ohtsuka *et al.*^[@bib6]^
  p.I203T                                                          c.608T\>C                55               1              5.60%                                      56 (11.0%)                                     Not pathogenic                      Kudo *et al.*,^[@bib21]^ Abe *et al.*^[@bib5]^

We detected nine pathogenic mutant alleles that had p.V37I, eight c.235delC, one p.\[G45E;Y136X\] and one p.R143W. We also detected two p.T8M, one p.I71T, one p.R127H and one p.F191L mutation, the pathogenesis of which had not been proven. *GJB2* carrier frequency in Japanese people was estimated to be 19/509 (3.73%).

Mutations screened by Invader assay covered by the Japanese National Health Insurance (Abe *et al.*^[@bib10]^).

Variants possibly representing non-pathogenic polymorphisms (Ohtuska *et al.*^[@bib6]^).
